CLPBY (Coloplast AS) Total Long-Term Liabilities: $4,304 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLPBY Coloplast AS CLPBY
77 GF Score
Price $6.74
GF Value $13.05
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Coloplast AS Total Long-Term Liabilities?

Coloplast AS CLPBY -0.88% 77 Total Long-Term Liabilities is $4,304 Mil as of Mar. 2026. GuruFocus rates CLPBY with a GF Score™ of 77/100 and a GF Value™ of $13.05 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Coloplast AS's Total Long-Term Liabilities for the quarter that ended in Mar. 2026 was $4,304 Mil.

Coloplast AS Total Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Coloplast AS's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coloplast AS Total Long-Term Liabilities Chart

Coloplast AS Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 215.01 2,902.49 2,082.09 2,966.21 4,047.81

Coloplast AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,079.01 3,228.05 4,047.81 4,243.07 4,304.05
CLPBY
77GF Score
Coloplast AS CLPBY
Total Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coloplast AS Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

What does a Total Long-Term Liabilities of $4,304 Mil mean?
Coloplast AS (CLPBY) has a Total Long-Term Liabilities of $4,304 Mil as of Mar. 2026. Toal Long-Term Liabilities is the obiligation expected to be repaid beyond the following twelve months or one business cycle. View historical data on Coloplast AS and its competitors.
Is Coloplast AS's Total Long-Term Liabilities too high?
Coloplast AS's current Total Long-Term Liabilities is $4,304 Mil. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Total Long-Term Liabilities compare to ISRG and BDX?
Coloplast AS's Total Long-Term Liabilities of $4,304 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Liabilities for a Medical Devices & Instruments company?
A good Total Long-Term Liabilities depends on the Medical Devices & Instruments industry context. However, Total Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Liabilities mean?
A high Total Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Toal Long-Term Liabilities is the obiligation expected to be repaid beyond the following twelve months or one business cycle. View historical data on Coloplast AS and its competitors. Coloplast AS's current Total Long-Term Liabilities is $4,304 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.74 — trading 48.4% below its estimated fair value. The current Total Long-Term Liabilities is $4,304 Mil. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Liabilities calculated?
Total Long-Term Liabilities is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Total Long-Term Liabilities is $4,304 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coloplast AS (CLPBY) Overvalued in 2026?

Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued. The current stock price of $6.74 is trading 48.4% below its estimated GF Value™ of $13.05. GuruFocus considers Coloplast AS to be Significantly Undervalued.

Key valuation signals for CLPBY:

  • Total Long-Term Liabilities: $4,304 Mil
  • GF Value™: $13.05 vs. price of $6.74 (48.4% below fair value)
  • GF Score™: 77/100 with 6 warning signs

No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coloplast AS Business Description

Address Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score

Get the complete analysis for CLPBY

Total Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.74
Price
$13.05
GF Value